Medicare ESA Coverage Will Not Experiment With Clinical Trial Approach

CMS has abandoned the idea of limiting some uses of erythropoiesis-stimulating agents to a research trial setting, despite receiving public comments that the "coverage with evidence development" approach may be acceptable in some circumstances